Silver Book Fact

After 54 weeks of receiving bevacizumab, wet age-realted macular degeneration (AMD) patients were more likely to gain at least 6 letters of contrast sensitivity than patikents recieving standard care–35.4% versus 15.2%.

Patel, J. Praveen, Fred K. Chen, Lyndon Da Cruz, Gary S. Rubin, Adnan Rufail; for the ABC Trial Study Group. Contrast Sensitivity Outcomes in the ABC Trial: A Randomized Trial of Bevacizumab for Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. February 2011; 52(6): 3089-93. http://www.iovs.org/content/early/2011/02/09/iovs.10-6208.full.pdf

Reference

Title
Contrast Sensitivity Outcomes in the ABC Trial: A Randomized Trial of Bevacizumab for Neovascular Age-Related Macular Degeneration
Publication
Invest Ophthalmol Vis Sci
Publication Date
February 2011
Authors
Patel, J. Praveen, Fred K. Chen, Lyndon Da Cruz, Gary S. Rubin, Adnan Rufail; for the ABC Trial Study Group
Volume & Issue
Volume 52, Issue 6
Pages
3089-93
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Treatments that have been found to delay or prevent diabetic retinopathy save the U.S. $1.6 billion annually.  
  • After 9 years of tight blood pressure control, patients with type 2 diabetes had a 34% reduction in retinopathy progression and a 47% reduction in risk of visual acuity deterioration…  
  • Nearly 50% of diabetic retinopathy patients who received ranibizumab–an anti-VEGF drug–experienced substantial visual improvement after a year of injections  
  • Lucentis to treat wet age-related macular degeneration (AMD)
    An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25%…  
  • Of the 8 Million older Americans at high risk of developing advanced age-related macular degeneration (AMD), 1.3 million will develop advanced AMD within 5 years.  However the NEI-sponsored Age-Related Eye…